ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	CFI-402257 Sensitive: B - Late Trials CFI-402257 Sensitive : B	CFI-402257 Sensitive: B - Late Trials CFI-402257 Sensitive : B
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	dasatinib + nilotinib + YD312 + S81694 Sensitive: D – Preclinical dasatinib + nilotinib + YD312 + S81694 Sensitive : D	dasatinib + nilotinib + YD312 + S81694 Sensitive: D – Preclinical dasatinib + nilotinib + YD312 + S81694 Sensitive : D
BCR-ABL1 E255K	B Acute Lymphoblastic Leukemia	BCR-ABL1 E255K	B Acute Lymphoblastic Leukemia	S81694 Sensitive: D – Preclinical S81694 Sensitive : D	S81694 Sensitive: D – Preclinical S81694 Sensitive : D
RB1 negative	Triple Negative Breast Cancer	RB1 negative	Triple Negative Breast Cancer	VRN08 Sensitive: D – Preclinical VRN08 Sensitive : D	VRN08 Sensitive: D – Preclinical VRN08 Sensitive : D

TTK inhibitor

Associations(4)